Skip to main content

Neurotoxic protein oligomerisation associated with polyglutamine diseases

Acta Neuropathologica volume 120, pages 419–437 (2010)Cite this article

Abstract

Polyglutamine (polyQ) diseases are associated with a CAG/polyQ expansion mutation in unrelated proteins. Upon elongation of the glutamine tract, disease proteins aggregate within cells, mainly in the central nervous system (CNS) and this aggregation process is associated with neurotoxicity. However, it remains unclear to what extent and how this aggregation causes neuronal dysfunction in the CNS. Aiming at preventing neuronal dysfunction, it will be crucial to determine the links between aggregation and cellular dysfunction, understand the folding pathway of polyQ proteins and discover the relative neurotoxicity of polyQ protein species formed along the aggregation pathway. Here, we review what is known about conformations of polyQ peptides and proteins in their monomeric state from experimental and modelling data, how conformational changes of polyQ proteins relate to their oligomerisation and morphology of aggregates and which cellular function are impaired by oligomers, in vitro and in vivo. We also summarise the key modulatory cellular mechanisms and co-factors, which could affect the folding pathway and kinetics of polyQ aggregation. Although many studies have investigated the relationship between polyQ aggregation and toxicity, these have mainly focussed on investigating changes in the formation of the classical hallmark of polyQ diseases, i.e. microscopically visible inclusion bodies. However, recent studies in which oligomeric species have been considered start to shed light on the identity of neurotoxic oligomeric species. Initial evidence suggests that conformational changes induced by polyQ expansions and their surrounding sequence lead to the formation of particular oligomeric intermediates that may differentially affect neurotoxicity.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Adachi H, Kume A, Li M et al (2001) Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum Mol Genet 10:1039–1048

    PubMed  Article  CAS  Google Scholar 

  2. Aiken CT, Steffan JS, Guerrero CM et al (2009) Phosphorylation of threonine-3: implications for huntingtin aggregation and neurotoxicity. J Biol Chem 284:29427–29436

    PubMed  Article  CAS  Google Scholar 

  3. Allsop D, Mayes J, Moore S, Masad A, Tabner BJ (2008) Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease. Biochem Soc Trans 36:1293–1298

    PubMed  Article  CAS  Google Scholar 

  4. Altschuler EL, Hud NV, Mazrimas JA, Rupp B (1997) Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res 50:73–75

    PubMed  Article  CAS  Google Scholar 

  5. Ambrose CM, Duyao MP, Barnes G et al (1994) Structure and expression of the Huntington’s disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 20:27–38

    PubMed  Article  CAS  Google Scholar 

  6. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810

    PubMed  Article  CAS  Google Scholar 

  7. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R (2007) Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 16:2600–2615

    PubMed  Article  CAS  Google Scholar 

  8. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319:916–919

    PubMed  Article  CAS  Google Scholar 

  9. Barton S, Jacak R, Khare SD, Ding F, Dokholyan NV (2007) The length dependence of the PolyQ-mediated protein aggregation. J Biol Chem 282:25487–25492

    PubMed  Article  CAS  Google Scholar 

  10. Bauer PO, Nukina N (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 110:1737–1765

    PubMed  Article  CAS  Google Scholar 

  11. Becher MW, Kotzuk JA, Sharp AH et al (1998) Intranuclear neuronal inclusions in Huntington’s disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4:387–397

    PubMed  Article  CAS  Google Scholar 

  12. Becker M, Martin E, Schneikert J, Krug HF, Cato ACB (2000) Cytoplasmic localization and the choice of ligand determine aggregate formation by androgen receptor with amplified polyglutamine stretch. J Cell Biol 149:255–262

    PubMed  Article  CAS  Google Scholar 

  13. Behrends C, Langer CA, Boteva R et al (2006) Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 23:887–897

    PubMed  Article  CAS  Google Scholar 

  14. Bennett EJ, Bence NF, Jayakumar R, Kopito RR (2005) Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17:351–365

    PubMed  Article  CAS  Google Scholar 

  15. Bevivino AE, Loll PJ (2001) An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta-fibrils. Proc Natl Acad Sci USA 98:11955–11960

    PubMed  Article  CAS  Google Scholar 

  16. Bhattacharyya A, Thakur AK, Chellgren VM et al (2006) Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol 355:524–535

    PubMed  Article  CAS  Google Scholar 

  17. Bhattacharyya AM, Thakur AK, Wetzel R (2005) Polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc Natl Acad Sci USA 102:15400–15405

    PubMed  Article  CAS  Google Scholar 

  18. Bhutani N, Venkatraman P, Goldberg AL (2007) Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO J 26:1385–1396

    PubMed  Article  CAS  Google Scholar 

  19. Bocharova NA, Sokolov SS, Knorre DA, Skulachev VP, Severin FF (2008) Unexpected link between anaphase promoting complex and the toxicity of expanded polyglutamines expressed in yeast. Cell Cycle 7:3943–3946

    PubMed  CAS  Google Scholar 

  20. Bodner RA, Outeiro TF, Altmann S et al (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases. Proc Natl Acad Sci USA 103:4246–4251

    PubMed  Article  CAS  Google Scholar 

  21. Bradford J, Shin J-Y, Roberts M, Wang C-E, Li X-J, Li S (2009) Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 106:22480–22485

    PubMed  Article  Google Scholar 

  22. Bradford J, Shin J-Y, Roberts M et al (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of huntington disease mice. J Biol Chem 285:10653–10661

    PubMed  Article  CAS  Google Scholar 

  23. Burnett B, Li F, Pittman RN (2003) The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 12:3195–3205

    PubMed  Article  CAS  Google Scholar 

  24. Busch A, Engemann S, Lurz R, Okazawa H, Lehrach H, Wanker EE (2003) Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin. J Biol Chem 278:41452–41461

    PubMed  Article  CAS  Google Scholar 

  25. Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci 6:919–930

    PubMed  Article  CAS  Google Scholar 

  26. Chai Y, Shao J, Miller VM, Williams A, Paulson HL (2002) Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci USA 99:9310–9315

    PubMed  Article  CAS  Google Scholar 

  27. Charles V, Mezey E, Reddy PH et al (2000) Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. Neurosci Lett 289:29–32

    PubMed  Article  CAS  Google Scholar 

  28. Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ et al (2006) Decreased association of the transcription factor Sp1 with genes downregulated in Huntington’s disease. Neurobiol Dis 22:233–241

    PubMed  Article  CAS  Google Scholar 

  29. Chen H-K, Fernandez-Funez P, Acevedo SF et al (2003) Interaction of Akt-phosphorylated Ataxin-1 with 14–3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113:457–468

    PubMed  Article  CAS  Google Scholar 

  30. Chen S, Berthelier V, Hamilton JB, O’Nuallai B, Wetzel R (2002) Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41:7391–7399

    PubMed  Article  CAS  Google Scholar 

  31. Chen S, Berthelier V, Yang W, Wetzel R (2001) Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 311:173–182

    PubMed  Article  CAS  Google Scholar 

  32. Chen S, Ferrone FA, Wetzel R (2002) Huntington’s disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci USA 99:11884–11889

    PubMed  Article  CAS  Google Scholar 

  33. Cornett J, Cao F, Wang C-E et al (2005) Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 37:198–204

    PubMed  Article  CAS  Google Scholar 

  34. Crick SL, Jayaraman M, Frieden C, Wetzel R, Pappu RV (2006) Fluorescence correlation spectroscopy shows that monomeric polyglutamine molecules form collapsed structures in aqueous solutions. Proc Natl Acad Sci USA 103:16764–16769

    PubMed  Article  CAS  Google Scholar 

  35. Dahlgren PR, Karymov MA, Bankston J et al (2005) Atomic force microscopy analysis of the huntington protein nanofibril formation. Nanomedicine 1:52–57

    PubMed  CAS  Google Scholar 

  36. Davidson JD, Riley B, Burright EN, Duvick LA, Zoghbi HY, Orr HT (2000) Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein. Hum Mol Genet 9:2305–2312

    PubMed  CAS  Google Scholar 

  37. Davies S, Turmaine M, Cozens B et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548

    PubMed  Article  CAS  Google Scholar 

  38. de Pril R, Fischer DF, Roos RAC, van Leeuwen FW (2007) Ubiquitin-conjugating enzyme E2–25 K increases aggregate formation and cell death in polyglutamine diseases. Mol Cell Neurosci 34:10–19

    PubMed  Article  CAS  Google Scholar 

  39. Deepak S, Leonid MS, Hideyo I, Ronald W, Daniel AK (2005) Polyglutamine homopolymers having 8–45 residues form slablike beta-crystallite assemblies. Proteins 61:398–411

    Article  CAS  Google Scholar 

  40. Dehay B, Weber C, Trottier Y, Bertolotti A (2007) Mapping of the epitope of monoclonal antibody 2B4 to the proline-rich region of human huntingtin, a region critical for aggregation and toxicity. Biotechnol J 2:559–564

    PubMed  Article  CAS  Google Scholar 

  41. DiFiglia M, Sapp E, Chase K et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993

    PubMed  Article  CAS  Google Scholar 

  42. DiFiglia M, Sapp E, Chase K et al (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14:1075–1081

    PubMed  Article  CAS  Google Scholar 

  43. Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K (2003) Ataxin-3 interactions with Rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol 23:6469–6483

    PubMed  Article  CAS  Google Scholar 

  44. Dougan L, Li J, Badilla CL, Berne BJ, Fernandez JM (2009) Single homopolypeptide chains collapse into mechanically rigid conformations. Proc Natl Acad Sci USA 106:12605–12610

    PubMed  Article  Google Scholar 

  45. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci USA 103:11045–11050

    PubMed  Article  CAS  Google Scholar 

  46. Ellisdon AM, Thomas B, Bottomley SP (2006) The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem 281:16888–16896

    PubMed  Article  CAS  Google Scholar 

  47. Emamian ES, Kaytor MD, Duvick LA et al (2003) Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38:375–387

    PubMed  Article  CAS  Google Scholar 

  48. Faber PW, Alter JR, MacDonald ME, Hart AC (1999) Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA 96:179–184

    PubMed  Article  CAS  Google Scholar 

  49. Fei E, Jia N, Zhang T et al (2007) Phosphorylation of ataxin-3 by glycogen synthase kinase 3 beta at serine 256 regulates the aggregation of ataxin-3. Biochem Biophys Res Com 357:487–492

    PubMed  Article  CAS  Google Scholar 

  50. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B et al (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408:101–106

    PubMed  Article  CAS  Google Scholar 

  51. Forman MS, Trojanowski JQ, Lee VMY (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10:1055–1063

    PubMed  Article  CAS  Google Scholar 

  52. Fox JH, Kama JA, Lieberman G et al (2007) Mechanisms of copper ion mediated huntington’s disease progression. PLoS One 2:e334

    PubMed  Article  CAS  Google Scholar 

  53. Frontali M (2001) Spinocerebellar ataxia type 6: channelopathy or glutamine repeat disorder? Brain Res Bull 56:227–231

    PubMed  Article  CAS  Google Scholar 

  54. Frost B, Diamond MI (2009) The expanding realm of prion phenomena in neurodegenerative disease. Prion 3:74–77

    PubMed  Article  CAS  Google Scholar 

  55. Funderburk SF, Shatkina L, Mink S, Weis Q, Weg-Remers S, Cato ACB (2009) Specific N-terminal mutations in the human androgen receptor induce cytotoxicity. Neurobiol Aging 30:1851–1864

    PubMed  Article  CAS  Google Scholar 

  56. Gales L, Cortes L, Almeida C et al (2005) Towards a structural understanding of the fibrillization pathway in Machado-Joseph’s disease: trapping early oligomers of non-expanded ataxin-3. J Mol Biol 353:642–654

    PubMed  Article  CAS  Google Scholar 

  57. Gauthier LR, Charrin BC, Borrell-Pagès M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127–138

    PubMed  Article  CAS  Google Scholar 

  58. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI (2006) Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311:1471–1474

    PubMed  Article  CAS  Google Scholar 

  59. Goehler H, Droge A, Lurz R, Schnoegl S, Chernoff YO, Wanker EE (2010) Pathogenic polyglutamine tracts are potent inducers of spontaneous Sup35 and Rnq1 amyloidogenesis. PLoS One 5:e9642

    PubMed  Article  CAS  Google Scholar 

  60. Gong B, Lim MCY, Wanderer J, Wyttenbach A, Morton AJ (2008) Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington’s disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull 75:146–157

    PubMed  Article  CAS  Google Scholar 

  61. Gunawardena S, Her L-S, Brusch RG et al (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic PolyQ proteins in drosophila. Neuron 40:25–40

    PubMed  Article  CAS  Google Scholar 

  62. Hackam AS, Singaraja R, Wellington CL et al (1998) The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 141:1097–1105

    PubMed  Article  CAS  Google Scholar 

  63. Hackam AS, Wellington CL, Hayden MR (1998) The fatal attraction of polyglutamine-containing proteins. Clin Genet 53:233–242

    PubMed  Article  CAS  Google Scholar 

  64. Hands S, Mason R, Sajjad MU, Giorgini F, Wyttenbach A (2010) Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington’s disease. Biochem Soc Trans 38:552–558

    PubMed  Article  CAS  Google Scholar 

  65. Hands S, Sinadinos C, Wyttenbach A (2008) Polyglutamine gene function and dysfunction in the ageing brain. Biochim Biophys Acta 1779:507–521

    PubMed  CAS  Google Scholar 

  66. Harrison P, Gerstein M (2003) A method to assess compositional bias in biological sequences and its application to prion-like glutamine/asparagine-rich domains in eukaryotic proteomes. Genome Biol 4:R40

    PubMed  Article  Google Scholar 

  67. Helmlinger D, Hardy S, Abou-Sleymane G et al (2006) Glutamine-expanded Ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol 4:e67

    PubMed  Article  CAS  Google Scholar 

  68. Hollenbach B, Scherzinger E, Schweiger K, Lurz R, Lehrach H, Wanker EE (1999) Aggregation of truncated GST–HD exon 1 fusion proteins containing normal range and expanded glutamine repeats. Philos Trans R Soc B Biol Sci 354:991–994

    Article  CAS  Google Scholar 

  69. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI (2004) Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 23:4307–4318

    PubMed  Article  CAS  Google Scholar 

  70. Holmberg M, Duyckaerts C, Durr A et al (1998) Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 7:913–918

    PubMed  Article  CAS  Google Scholar 

  71. Humbert S, Bryson EA, Cordelières FP et al (2002) The IGF-1/Akt pathway is neuroprotective in Huntington’s Disease and involves huntingtin phosphorylation by Akt. Dev Cell 2:831–837

    PubMed  Article  CAS  Google Scholar 

  72. Ignatova Z, Gierasch LM (2006) Inhibition of protein aggregation in vitro and in vivo by a natural osmoprotectant. Proc Natl Acad Sci USA 103:13357–13361

    PubMed  Article  CAS  Google Scholar 

  73. Ignatova Z, Thakur AK, Wetzel R, Gierasch LM (2007) In-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence. J Biol Chem 282:36736–36743

    PubMed  Article  CAS  Google Scholar 

  74. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A (1996) Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 13:196–202

    PubMed  Article  CAS  Google Scholar 

  75. Iwata A, Christianson JC, Bucci M et al (2005) Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci USA 102:13135–13140

    PubMed  Article  CAS  Google Scholar 

  76. Jayaraman M, Kodali R, Wetzel R (2009) The impact of ataxin-1-like histidine insertions on polyglutamine aggregation. Protein Eng Des Sel 22:469–478

    PubMed  Article  CAS  Google Scholar 

  77. Jeong H, Then F, Melia TJ et al (2009) Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137:60–72

    PubMed  Article  CAS  Google Scholar 

  78. Kegel KB, Sapp E, Alexander J et al (2009) Polyglutamine expansion in huntingtin alters its interaction with phospholipids. J Neurochem 110:1585–1597

    PubMed  Article  CAS  Google Scholar 

  79. Kegel KB, Schewkunow V, Sapp E et al (2009) Polyglutamine expansion in huntingtin increases its insertion into lipid bilayers. Biochem Biophys Res Comm 387:472–475

    PubMed  Article  CAS  Google Scholar 

  80. Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I (2009) Secondary structure of huntingtin amino-terminal region. Structure 17:1205–1212

    PubMed  Article  CAS  Google Scholar 

  81. Kim S, Nollen EAA, Kitagawa K, Bindokas VP, Morimoto RI (2002) Polyglutamine protein aggregates are dynamic. Nat Cell Biol 4:826–831

    PubMed  Article  CAS  Google Scholar 

  82. Kim YJ, Yi Y, Sapp E et al (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington’s disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 98:12784–12789

    PubMed  Article  CAS  Google Scholar 

  83. Kitamura A, Kubota H, Pack C-G et al (2006) Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 8:1163–1169

    PubMed  Article  CAS  Google Scholar 

  84. Kuemmerle S, Gutekunst CA, Klein AM et al (1999) Huntington aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol 46:842–849

    PubMed  Article  CAS  Google Scholar 

  85. Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A (2009) Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One 4:e5727

    PubMed  Article  CAS  Google Scholar 

  86. Landles C, Sathasivam K, Weiss A et al (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington Disease. J Biol Chem 285:8808–8823

    PubMed  Article  CAS  Google Scholar 

  87. Lashuel HA, Petre BM, Wall J et al (2002) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089–1102

    PubMed  Article  CAS  Google Scholar 

  88. Lathrop RH, Casale M, Tobias DJ, Marsh JL, Thompson L (1998) Modeling protein homopolymeric repeats: possible polyglutamine structural motifs for Huntington’s disease. Proc Int Conf Intell Syst Mol Biol 6:105–114

    PubMed  CAS  Google Scholar 

  89. Lee CC, Walters RH, Murphy RM (2007) Reconsidering the mechanism of polyglutamine peptide aggregation. Biochemistry 46:12810–12820

    PubMed  Article  CAS  Google Scholar 

  90. Lee J-M, Ivanova EV, Seong IS et al (2007) Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 3:e135

    PubMed  Article  CAS  Google Scholar 

  91. Lee K-J, Panzera A, Rogawski D, Greene LE, Eisenberg E (2007) Cellular prion protein (PrPC) protects neuronal cells from the effect of huntingtin aggregation. J Cell Sci 120:2663–2671

    PubMed  Article  CAS  Google Scholar 

  92. Lee W-CM, Yoshihara M, Littleton JT (2004) Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington’s disease. Proc Natl Acad Sci USA 101:3224–3229

    PubMed  Article  CAS  Google Scholar 

  93. Legleiter J, Lotz GP, Miller J et al (2009) Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem 284:21647–21658

    PubMed  Article  CAS  Google Scholar 

  94. Legleiter J, Mitchell E, Lotz GP et al (2010) Mutant Huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 285:14777–14790

    PubMed  Article  CAS  Google Scholar 

  95. Li M, Miwa S, Kobayashi Y et al (1998) Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 44:249–254

    PubMed  Article  CAS  Google Scholar 

  96. Maat-Shieman ML, Dorsman JC, Smoor MA et al (1999) Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J Neuropathol Exp Neurol 58:129–137

    Article  Google Scholar 

  97. Macedo-Ribeiro S, Cortes L, Maciel P, Carvalho A (2009) Nucleocytoplasmic shuttling activity of Ataxin-3. PLoS One 4:e5834

    PubMed  Article  CAS  Google Scholar 

  98. Maltecca F, Filla A, Castaldo I et al (2003) Intergenerational instability and marked anticipation in SCA-17. Neurology 61:1441–1443

    PubMed  CAS  Google Scholar 

  99. Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506

    PubMed  Article  CAS  Google Scholar 

  100. Manto M-U (2005) The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 4:2–6

    PubMed  Article  CAS  Google Scholar 

  101. Marchut AJ, Hall CK (2006) Spontaneous formation of annular structures observed in molecular dynamics simulations of polyglutamine peptides. Comput Biol Chem 30:215–218

    PubMed  Article  CAS  Google Scholar 

  102. Marsh JL, Walker H, Theisen H et al (2000) Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 9:13–25

    PubMed  Article  CAS  Google Scholar 

  103. Masino L, Kelly G, Leonard K, Trottier Y, Pastore A (2002) Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett 513:267–272

    PubMed  Article  CAS  Google Scholar 

  104. Masino L, Pastore A (2002) Glutamine repeats: structural hypotheses and neurodegeneration. Biochem Soc Trans 30:548–551

    PubMed  Article  CAS  Google Scholar 

  105. McEwan I (2004) Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr Relat Cancer 11:281–293

    PubMed  Article  CAS  Google Scholar 

  106. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, Sherman MY (2002) Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 157:997–1004

    PubMed  Article  CAS  Google Scholar 

  107. Milnerwood AJ, Raymond LA (2007) Corticostriatal synaptic function in mouse models of Huntington’s disease: early effects of huntingtin repeat length and protein load. J Physiol 585:817–831

    PubMed  Article  CAS  Google Scholar 

  108. Monoi H (1995) New tubular single-stranded helix of poly-l-amino acids suggested by molecular mechanics calculations: I. Homopolypeptides in isolated environments. Biophys J 69:1130–1141

    PubMed  Article  CAS  Google Scholar 

  109. Monoi H, Futaki S, Kugimiya S-I, Minakata H, Yoshihara K (2000) Poly-l-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys J 78:2892–2899

    PubMed  Article  CAS  Google Scholar 

  110. Muchowski PJ, Ning K, D’Souza-Schorey C, Fields S (2002) Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci USA 99:727–732

    PubMed  Article  CAS  Google Scholar 

  111. Mukai H, Isagawa T, Goyama E et al (2005) Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc Natl Acad Sci USA 102:10887–10892

    PubMed  Article  CAS  Google Scholar 

  112. Mukherjee S, Thomas M, Dadgar N, Lieberman AP, Iniquez-Lluhi JA (2009) Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J Biol Chem 284:21296–21306

    PubMed  Article  CAS  Google Scholar 

  113. Nagai Y, Inui T, Popiel HA et al (2007) A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 14:332–340

    PubMed  Article  CAS  Google Scholar 

  114. Nekooki-Machida Y, Kurosawa M, Nukina N, Ito K, Oda T, Tanaka M (2009) Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci USA 106:9679–9684

    PubMed  Article  Google Scholar 

  115. Nonhoff U, Ralser M, Welzel F et al (2007) Ataxin-2 interacts with the DEAD/H-Box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell 18:1385–1396

    PubMed  Article  CAS  Google Scholar 

  116. Ono K, Condron MM, Teplow DB (2009) Structure neurotoxicity relationships of amyloid-beta protein oligomers. Proc Natl Acad Sci USA 106:14745–14750

    PubMed  Article  Google Scholar 

  117. Orr AL, Li S, Wang C-E et al (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28:2783–2792

    PubMed  Article  CAS  Google Scholar 

  118. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Ann Rev Neurosci 30:575–621

    PubMed  Article  CAS  Google Scholar 

  119. Parekh-Olmedo H, Wang J, Gusella J, Kmiec E (2004) Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine. J Mol Neurosci 24:257–267

    PubMed  Article  CAS  Google Scholar 

  120. Paulson HL, Perez MK, Trottier Y et al (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19:333–344

    PubMed  Article  CAS  Google Scholar 

  121. Pavese N, Gerhard A, Tai YF et al (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66:1638–1643

    PubMed  Article  CAS  Google Scholar 

  122. Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN (1998) Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol 143:1457–1470

    PubMed  Article  CAS  Google Scholar 

  123. Perutz MF, Finch JT, Berriman J, Lesk A (2002) Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci USA 99:5591–5595

    PubMed  Article  CAS  Google Scholar 

  124. Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91:5355–5358

    PubMed  Article  CAS  Google Scholar 

  125. Poirier MA, Jiang H, Ross CA (2005) A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet 14:765–774

    PubMed  Article  CAS  Google Scholar 

  126. Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA (2002) Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 277:41032–41037

    PubMed  Article  CAS  Google Scholar 

  127. Popiel HA, Nagai Y, Onodera O et al (2004) Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity. Biochem Biophys Res Comm 317:1200–1206

    PubMed  Article  CAS  Google Scholar 

  128. Pratt G, Rechsteiner M (2008) Proteasomes cleave at multiple sites within polyglutamine tracts. J Biol Chem 283:12919–12925

    PubMed  Article  CAS  Google Scholar 

  129. Quintanilla RA, Johnson GVW (2009) Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res Bull 80:242–247

    PubMed  Article  CAS  Google Scholar 

  130. Quraishe S, Asuni A, Boelens WC, O’Connor V, Wyttenbach A (2008) Expression of the small heat shock protein family in the mouse CNS: differential anatomical and biochemical compartmentalization. Neuroscience 153:483–491

    PubMed  Article  CAS  Google Scholar 

  131. Rangone H, Poizat G, Troncoso J et al (2004) The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 19:273–279

    PubMed  Article  Google Scholar 

  132. Raspe M, Gillis J, Krol H et al (2009) Mimicking proteasomal release of polyglutamine peptides initiates aggregation and toxicity. J Cell Sci 122:3262–3271

    PubMed  Article  CAS  Google Scholar 

  133. Ravikumar B, Stewart A, Kita H, Kato K, Duden R, Rubinsztein DC (2003) Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum Mol Genet 12:985–994

    PubMed  Article  CAS  Google Scholar 

  134. Ren P-H, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 11:219–225

    PubMed  Article  CAS  Google Scholar 

  135. Ricchelli F, Fusi P, Tortora P et al (2007) Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis. Int J Biochem Cell Biol 39:966–977

    PubMed  Article  CAS  Google Scholar 

  136. Rockabrand E, Slepko N, Pantalone A et al (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16:61–77

    PubMed  Article  CAS  Google Scholar 

  137. Rousseau E, Dehay B, Ben-Haïem L, Trottier Y, Morange M, Bertolotti A (2004) Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation. Proc Natl Acad Sci USA 101:9648–9653

    PubMed  Article  CAS  Google Scholar 

  138. Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443:780–786

    PubMed  Article  CAS  Google Scholar 

  139. Sapp E, Kegel KB, Aronin N et al (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161–172

    PubMed  CAS  Google Scholar 

  140. Sapp E, Penney J, Young A, Aronin N, Vonsattel J-P, DiFiglia M (1999) Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58:165–173

    PubMed  Article  CAS  Google Scholar 

  141. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A (2009) Huntington’s disease: the current state of research with peripheral tissues. Exp Neurol 219:385–397

    PubMed  Article  CAS  Google Scholar 

  142. Sathasivam K, Hobbs C, Turmaine M et al (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8:813–822

    PubMed  Article  CAS  Google Scholar 

  143. Sathasivam K, Lane A, Legleiter J et al (2010) Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington’s disease. Hum Mol Genet 19:65–78

    PubMed  Article  CAS  Google Scholar 

  144. Satterfield TF, Jackson SM, Pallanck LJ (2002) A drosophila homolog of the polyglutamine disease gene sca2 is a dosage-sensitive regulator of actin filament formation. Genetics 162:1687–1702

    PubMed  CAS  Google Scholar 

  145. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55–66

    PubMed  Article  CAS  Google Scholar 

  146. Saunders HM, Bottomley SP (2009) Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins. Protein Eng Des Sel 22:447–451

    PubMed  Article  CAS  Google Scholar 

  147. Scherzinger E, Lurz R, Turmaine M et al (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549–558

    PubMed  Article  CAS  Google Scholar 

  148. Schiffer NW, Broadley SA, Hirschberger T et al (2007) Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J Biol Chem 282:9195–9203

    PubMed  Article  CAS  Google Scholar 

  149. Schiffer NW, Ceraline J, Hartl FU, Broadley SA (2008) N-terminal polyglutamine-containing fragments inhibit androgen receptor transactivation function. Biol Chem 389:1455–1466

    PubMed  Article  CAS  Google Scholar 

  150. Schilling B, Gafni J, Torcassi C et al (2006) Huntingtin phosphorylation sites mapped by mass spectrometry. J Biol Chem 281:23686–23697

    PubMed  Article  CAS  Google Scholar 

  151. Sen S, Dash D, Pasha S, Brahmachari SK (2003) Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: a molecular approach. Protein Sci 12:953–962

    PubMed  Article  CAS  Google Scholar 

  152. Sharma D, Sharma S, Pasha S, Brahmachari SK (1999) Peptide models for inherited neurodegenerative disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions. FEBS Lett 456:181–185

    PubMed  Article  CAS  Google Scholar 

  153. Sikorski P, Atkins E (2005) New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecule 6:425–432

    Article  CAS  Google Scholar 

  154. Singhrao SK, Thomas P, Wood JD et al (1998) Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington’s, Alzheimer’s, and Pick’s Diseases. Exp Neurol 150:213–222

    PubMed  Article  CAS  Google Scholar 

  155. Squitieri F, Gellera C, Cannella M et al (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126:946–955

    PubMed  Article  Google Scholar 

  156. Steffan JS, Agrawal N, Pallos J et al (2004) SUMO modification of huntingtin and Huntington’s Disease pathology. Science 304:100–104

    PubMed  Article  CAS  Google Scholar 

  157. Stenoien DL, Mielke M, Mancini MA (2002) Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat Cell Biol 4:806–810

    PubMed  Article  CAS  Google Scholar 

  158. Suopanki J, Götz C, Lutsch G et al (2006) Interaction of huntingtin fragments with brain membranes; clues to early dysfunction in Huntington’s disease. J Neurochem 96:870–884

    PubMed  Article  CAS  Google Scholar 

  159. Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O (2008) Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet 17:345–356

    PubMed  Article  CAS  Google Scholar 

  160. Takahashi Y, Okamoto Y, Popiel HA et al (2007) Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J Biol Chem 282:24039–24048

    PubMed  Article  CAS  Google Scholar 

  161. Tam S, Geller R, Spiess C, Frydman J (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8:1155–1162

    PubMed  Article  CAS  Google Scholar 

  162. Tanaka M, Morishima I, Akagi T, Hashikawa T, Nukina N (2001) Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J Biol Chem 276:45470–45475

    PubMed  Article  CAS  Google Scholar 

  163. Temussi PA, Masino L, Pastore A (2003) From Alzheimer to Huntington: why is a structural understanding so difficult? EMBO J 22:355–361

    PubMed  Article  CAS  Google Scholar 

  164. Thakur AK, Jayaraman M, Mishra R et al (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16:380–389

    PubMed  Article  CAS  Google Scholar 

  165. Thakur AK, Wetzel R (2002) Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci USA 99:17014–17019

    PubMed  Article  CAS  Google Scholar 

  166. Tsai C-C, Kao H-Y, Mitzutani A et al (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci USA 101:4047–4052

    PubMed  Article  CAS  Google Scholar 

  167. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL (2004) Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14:95–104

    PubMed  Article  CAS  Google Scholar 

  168. Vitalis A, Lyle N, Pappu RV (2009) Thermodynamics of β-Sheet formation in polyglutamine. Biophys J 97:303–311

    PubMed  Article  CAS  Google Scholar 

  169. Vitalis A, Wang X, Pappu RV (2008) Atomistic simulations of the effects of polyglutamine chain length and solvent quality on conformational equilibria and spontaneous homodimerization. J Mol Biol 384:279–297

    PubMed  Article  CAS  Google Scholar 

  170. Vonsattel J (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115:55–69

    PubMed  Article  Google Scholar 

  171. Wacker JL, Huang S-Y, Steele AD et al (2009) Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington’s Disease. J Neurosci 29:9104–9114

    PubMed  Article  CAS  Google Scholar 

  172. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ (2004) Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol 11:1215–1222

    PubMed  Article  CAS  Google Scholar 

  173. Walsh R, Storey E, Stefani D, Kelly L, Turnbull V (2005) The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review. Neurotox Res 7:43–57

    PubMed  Article  CAS  Google Scholar 

  174. Walters RH, Murphy RM (2009) Examining polyglutamine peptide length: a connection between collapsed conformations and increased aggregation. J Mol Biol 393:978–992

    PubMed  Article  CAS  Google Scholar 

  175. Wang H, Lim PJ, Karbowski M, Monteiro MJ (2009) Effects of overexpression of Huntingtin proteins on mitochondrial integrity. Hum Mol Genet 18:737–752

    PubMed  Article  CAS  Google Scholar 

  176. Wang J, Wang C-E, Orr A, Tydlacka S, Li S-H, Li X-J (2008) Impaired ubiquitin-proteasome system activity in the synapses of Huntington’s disease mice. J Cell Biol 180:1177–1189

    PubMed  Article  CAS  Google Scholar 

  177. Wang Y, Meriin AB, Costello CE, Sherman MY (2007) Characterization of proteins associated with polyglutamine aggregates: a novel approach towards isolation of aggregates from protein conformation disorders. Prion 1:128–135

    PubMed  Article  Google Scholar 

  178. Weiss A, Klein C, Woodman B et al (2008) Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease. J Neurochem 104:846–858

    PubMed  CAS  Google Scholar 

  179. Wellington CL, Ellerby LM, Hackam AS et al (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273:9158–9167

    PubMed  Article  CAS  Google Scholar 

  180. Wexler NS (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA 101:3498–3503

    PubMed  Article  CAS  Google Scholar 

  181. Wiedemeyer R, Westermann F, Wittke I, Nowock J, Schwab M (2003) Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 22:401–411

    PubMed  Article  CAS  Google Scholar 

  182. Williams AJ, Knutson TM, Colomer Gould VF, Paulson HL (2009) In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol Dis 33:342–353

    PubMed  Article  CAS  Google Scholar 

  183. Williamson TE, Vitalis A, Crick SL, Pappu RV (2010) Modulation of polyglutamine conformations and dimer formation by the N-terminus of huntingtin. J Mol Biol 396:1230–1295

    Article  CAS  Google Scholar 

  184. Wood JD, Yuan J, Margolis RL et al (1998) Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. Mol Cell Neurosci 11:149–160

    PubMed  Article  CAS  Google Scholar 

  185. Wyttenbach A, Swartz J, Kita H et al (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington’s disease. Hum Mol Genet 10:1829–1845

    PubMed  Article  CAS  Google Scholar 

  186. Yamada M, Sato T, Shimohata T et al (2001) Interaction between neuronal intranuclear inclusions and promyelocytic leukemia protein nuclear and coiled bodies in CAG repeat diseases. Am J Pathol 159:1785–1795

    PubMed  CAS  Google Scholar 

  187. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s Disease. Cell 101:57–66

    PubMed  Article  CAS  Google Scholar 

  188. Zhang S, Xu L, Lee J, Xu T (2002) Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell 108:45–56

    PubMed  Article  CAS  Google Scholar 

  189. Zhou H, Li S-H, Li X-J (2001) Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. J Biol Chem 276:48417–48424

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

AW and SH thank the Medical Research Council for financial support.

Author information

Author notes

  1. Sarah L. Hands

    Present address: School of Physics, University of Southampton, Highfield, Southampton, SO17 1BJ, UK

Affiliations

  1. Southampton Neuroscience Group, School of Biological Sciences, University of Southampton, Southampton, SO16 7PX, UK

    Sarah L. Hands & Andreas Wyttenbach

Authors
  1. Sarah L. Hands
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Wyttenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Wyttenbach.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hands, S.L., Wyttenbach, A. Neurotoxic protein oligomerisation associated with polyglutamine diseases. Acta Neuropathol 120, 419–437 (2010). https://doi.org/10.1007/s00401-010-0703-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-010-0703-0

Keywords

  • Androgen Receptor
  • polyQ Disease
  • polyQ Protein
  • polyQ Expansion
  • polyQ Stretch